Supercharging a New FDA: Marty Makary on Science, Power & Patients

America's FDA takes 60 days just to acknowledge that a drug application is complete. China approves phase one trials in four weeks. This isn't about regulatory rigor versus recklessness , it's about bureaucratic bloat strangling American innovation while competitors sprint ahead.

Marty Makary, the surgeon and researcher tapped to lead the FDA, believes the agency has become a monument to administrative inefficiency disguised as scientific caution. His diagnosis is stark: "There is a race, and when we came to office, we were losing that race. We were behind. We were getting clocked by China, by Australia." The solution isn't protectionism but speed , using technology and common sense to strip away layers of bureaucratic sediment that have accumulated over decades.

Consider the absurdity Makary encountered at Johns Hopkins, where a simple nutrition survey took 18 months to wind through institutional review boards before ultimately being rejected. "At Johns Hopkins, I had a study, took a year and a half to go through the IRB. It was a survey. What are we worried about? It was a nutrition survey," Makary recounts. Meanwhile, Australia approves studies with a signature on a dotted line, and China runs circles around American researchers who spend more time navigating approval processes than conducting actual science.

This isn't just academic frustration. The regulatory sclerosis represents a strategic vulnerability. America's dominance in life sciences depends on maintaining the innovation edge that built companies like Moderna and Pfizer. But when bureaucracy becomes the primary product of regulatory agencies, that edge dulls quickly. Makary's plan attacks the problem with surgical precision: "Sixty days just for the FDA to tell you that your application is complete. We're gonna get that down to one day. We're gonna use AI."

The vaccine debate reveals another dimension of institutional dysfunction. Rather than defending an increasingly unpopular one-size-fits-all approach, Makary proposes strategic clarity. His team analyzed vaccination schedules across 20 developed countries and found that America recommends far more doses than international peers. "We looked at 20 other developed countries and found that not only are we the international outlier in how high the number of doses we recommend is, but that there's a consensus of a group of core essential vaccines," he explains. The response isn't anti-vaccine ideology but practical prioritization , identifying 38 core doses that constitute the essential foundation while acknowledging that trust has eroded through regulatory overreach.

This represents a profound shift from regulatory agencies that view skepticism as ignorance to be overcome through authority. Instead, Makary treats declining vaccination rates as a market signal about institutional credibility. When parents lose trust in health agencies, the solution isn't more mandates but better transparency about what actually matters versus what represents bureaucratic gold-plating.

The deeper problem extends beyond specific policies to the nature of bureaucratic incentives. Makary describes encountering an FDA employee whose entire job was replacing ink cartridges in fax machines. "The guy's job was the ink guy on the fax machine. Just to swap out the ink cartridge. There's a lot of that." This isn't just inefficiency , it's institutional capture by process over purpose.

The competitive threat is real and immediate. While American researchers navigate Byzantine approval processes, international competitors build advantages through speed and simplicity. Australia's streamlined contracting allows researchers to begin trials quickly, while American hospitals negotiate individual margins and customize contracts for every study. This isn't just slower , it's a systematic disadvantage in industries where first-mover advantages determine market leadership.

The stakes extend beyond drug development to America's position in the global knowledge economy. Regulatory agencies that prioritize process over results don't just slow innovation , they drive it offshore. When talented researchers can accomplish more in Melbourne or Shanghai than Baltimore, the brain drain becomes irreversible.

Watch for three indicators of whether Makary's reforms take hold: AI implementation in application processing, centralized IRB approval times, and international competitiveness metrics in clinical trial initiation. If FDA application acknowledgments still take weeks instead of days six months from now, the bureaucracy is winning. If American phase one trials remain slower than international competitors, the reforms are failing. The real test isn't whether the FDA becomes more user-friendly, but whether America stops losing the innovation race that ultimately determines economic and strategic leadership.